THERAPEUTIC POTENTIAL OF JASMINUM SAMBAC IN DIABETES: A REVIEW
Main Article Content
Keywords
Diabetes, Blood Glucose Level, Jasmine, Stevia
Abstract
Diabetes mellitus (DM) is a complex metabolic disorder characterized by consistently high blood glucose levels due to issues with insulin production or function. This condition disrupts the metabolism of carbohydrates, fats, and proteins and is primarily classified into Type 1 and Type 2 diabetes. Type 1 diabetes is an autoimmune disorder where the immune system destroys insulin-producing pancreatic cells, requiring lifelong insulin treatment and lifestyle changes. Type 2 diabetes involves insulin resistance and inadequate insulin production, often linked to obesity and lack of physical activity. Effective management includes lifestyle modifications, medications, and regular monitoring to avoid serious complications such as cardiovascular issues, nerve damage, and vision problems.
The document also explores the botanical features of jasmine and stevia. Jasmine (Jasminum Sambac) is prized for its fragrant flowers used in perfumes and cosmetics and thrives in warm, humid environments. It contains aromatic compounds like linalool and jasmones. Stevia (Stevia rebaudiana) is known for its sweet-tasting leaves, used as a natural sweetener due to compounds like stevioside and rebaudioside, which are significantly sweeter than sugar. Stevia is cultivated worldwide and valued for its sweetness without added calories and potential health benefits.
References
1. Adem, A. M., Andargie, A. A., Teshale, A. B., & Wolde, H. F. (2020). Incidence of diabetic foot ulcer and its predictors among diabetes mellitus patients at Felege Hiwot Referral Hospital, Bahir Dar, Northwest Ethiopia: a retrospective follow-up study. Diabetes, Metabolic Syndrome and Obesity, 3703-3711.
2. Di Iorgi, N., Napoli, F., Allegri, A. E. M., Olivieri, I., Bertelli, E., Gallizia, A., ... & Maghnie, M. (2012). Diabetes insipidus–diagnosis and management. Hormone research in paediatrics, 77(2), 69-84.
3. Norris, M. M. (2009). Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study. Diabetologia, 2064-2071.
4. Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014). Type 1 diabetes. The lancet, 383(9911), 69-82.
5. Kumar, R., Saha, P., Kumar, Y., Sahana, S., Dubey, A., & Prakash, O. (2020). A review on diabetes mellitus: type1 & Type2. World Journal of Pharmacy and Pharmaceutical Sciences, 9(10), 838-850.
6. Paschou, S. A., Papadopoulou-Marketou, N., Chrousos, G. P., & Kanaka-Gantenbein, C. (2018). On type 1 diabetes mellitus pathogenesis. Endocrine connections, 7(1), R38-R46.
7. Powers, A. C. (2021). Type 1 diabetes mellitus: much progress, many opportunities. The Journal of clinical investigation, 131(8).
8. Pociot, F., & McDermott, M. F. (2002). Genetics of type 1 diabetes mellitus. Genes & Immunity, 3(5), 235-249.
9. Morran, M. P., Vonberg, A., Khadra, A., & Pietropaolo, M. (2015). Immunogenetics of type 1 diabetes mellitus. Molecular aspects of medicine, 42, 42-60.
10. Ilonen, J., Lempainen, J., & Veijola, R. (2019). The heterogeneous pathogenesis of type 1 diabetes mellitus. Nature Reviews Endocrinology, 15(11), 635-650.
11. Daneman, D. (2006). Type 1 diabetes. The Lancet, 367(9513), 847-858.
12. DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., ... & Weiss, R. (2015). Type 2 diabetes mellitus. Nature reviews Disease primers, 1(1), 1-22.
13. Chatterjee, S., Khunti, K., & Davies, M. J. (2017). Type 2 diabetes. The lancet, 389(10085), 2239-2251.
14. Vijan, S. (2010). Type 2 diabetes. Annals of internal medicine, 152(5), ITC3-1.
15. Lebovitz, H. E. (1999). Type 2 diabetes: an overview. Clinical chemistry, 45(8), 1339-1345.
16. Taylor, S. I. (1999). Deconstructing type 2 diabetes. Cell, 97(1), 9-12.
17. Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., ... & Martín, C. (2020). Pathophysiology of type 2 diabetes mellitus. International journal of molecular sciences, 21(17), 6275.
18. Chen, L., Magliano, D. J., & Zimmet, P. Z. (2012). The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nature reviews endocrinology, 8(4), 228-236.
19. Tuomi, T. (2005). Type 1 and type 2 diabetes: what do they have in common? Diabetes, 54(suppl_2), S40-S45.
20. Scheen, A. J. (2003). Pathophysiology of type 2 diabetes. Acta Clinica Belgica, 58(6), 335341.
21. Nolan, C. J., Damm, P., & Prentki, M. (2011). Type 2 diabetes across generations: from pathophysiology to prevention and management. The Lancet, 378(9786), 169-181.
22. Deshpande, A. D., Harris-Hayes, M., & Schootman, M. (2008). Epidemiology of diabetes and diabetes-related complications. Physical therapy, 88(11), 1254-1264.
23. Papatheodorou, K., Banach, M., Bekiari, E., Rizzo, M., & Edmonds, M. (2018). Complications of diabetes 2017. Journal of diabetes research, 2018.
24. Scott A., Chambers D., Goyder E., O’Cathain A. Socioeconomic inequalities in mortality, morbidity, and diabetes management for adults with type 1 diabetes: a systematic review. PLoS One. 2017;12.
25. Shuldiner A. R., Yang R., Gong D.-W. Resistin, obesity, and insulin resistance — the emerging role of the adipocyte as an endocrine organ. The New England Journal of Medicine. 2001;345(18):1345–1346.
26. Banday, M. Z., Sameer, A. S., & Nissar, S. (2020). Pathophysiology of diabetes: An overview. Avicenna journal of medicine, 10(04), 174-188. https://en.wikipedia.org/wiki/Diabetes
27. Duby JJ, Campbell RK, Setter SM, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 2004; 61: 160-73
28. Ng DP, Krolewski AS. Molecular genetic approaches for studying the etiology of diabetic nephropathy. Curr Mol Med 2005; 5: 509- 25.
29. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nature Clin Prac Endocrinol Metab 2008; 4: 444-52.
30. Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endo Metab Disor 2008; 9: 315-27.
31. Pendsey S. Understanding diabetic foot. Int J Diabetes Dev Ctries 2010; 30: 75-9.
32. Oumeish OY. Skin disorders in patients with diabetes. Clin Dermatol 2008; 26: 235-42.
33. Lotfy, M., Adeghate, J., Kalasz, H., Singh, J., & Adeghate, E. (2017). Chronic complications of diabetes mellitus: a mini review. Current diabetes reviews, 13(1), 3-10.
34. https://en.wikipedia.org/wiki/Jasmine
35. Mourya, N. M. N., Bhopte, D. B. D., & Sagar, R. S. R. (2017). A review on Jasminum Sambac: A potential medicinal plant. International Journal of Indigenous Herbs and Drugs, 13-16.
36. Joy, P., & Raja, D. P. (2008). Anti-bacterial activity studies of Jasminum grandiflorum and Jasminum sambac. Ethnobotanical leaflets, 2008(1), 59.
37. Ahmed, N., Hanani, Y. A., Ansari, S. Y., & Anwar, S. (2016). Jasmine (Jasminum Sambac L., Oleaceae) oils. In Essential oils in food preservation, flavor, and safety (pp. 487-494). Academic Press.
38. Silalahi, M. (2023). Jasmine (Jasminum sambac (L.) Aiton): potential utilization and bioactivity. Asian Journal of Research in Agriculture and Forestry, 9(2), 28-36. https://en.wikipedia.org/wiki/Stevia_rebaudiana
39. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/stevia
40. Yadav, A. K., Singh, S., Dhyani, D., & Ahuja, P. S. (2011). A review on the improvement of stevia [Stevia rebaudiana (Bertoni)]. Canadian journal of plant science, 91(1), 1-27.
41. Goyal, S. K., Samsher, N., & Goyal, R. (2010). Stevia (Stevia rebaudiana) a bio-sweetener: a review. International journal of food sciences and nutrition, 61(1), 1-10.
42. Ghaheri, M., Kahrizi, D., & Bahrami, G. (2017). Effect of mannitol on some morphological characteristics of in vitro stevia rebaudiana Bertoni. Biharean Biologist, 11(2), 94-97.
43. Mlambo, R., Wang, J., & Chen, C. (2022). Stevia rebaudiana, a versatile food ingredient: The chemical composition and medicinal properties. Journal of Nanomaterials, 2022(1), 3573005.
44. Jan, S. A., Habib, N., Shinwari, Z. K., Ali, M., & Ali, N. (2021). The anti-diabetic activities of natural sweetener plant Stevia: an updated review. SN Applied Sciences, 3, 1-6.
45. Pérez, E., González, C., Vaillant, F., & Lares, M. (2016). Stevia derivative and its potential uses in diabetic-directed foods. Review. Journal of Nutrients, 3(1), 1-20.
46. Chowdhury, A. I., Rahanur Alam, M., Raihan, M. M., Rahman, T., Islam, S., & Halima, O. (2022). Effect of stevia leaves (Stevia rebaudiana Bertoni) on diabetes: A systematic review and meta‐analysis of preclinical studies. Food Science & Nutrition, 10(9), 2868-2878.
47. Masoumi, S. J., Ranjbar, S., & Keshavarz, V. (2020). The effectiveness of stevia in diabetes mellitus: A review. International journal of nutrition sciences, 5(2), 45-49.
48. Shivanna, N., Naika, M., Khanum, F., & Kaul, V. K. (2013). Antioxidant, anti-diabetic and renal protective properties of Stevia rebaudiana. Journal of Diabetes and its Complications, 27(2), 103-113.
2. Di Iorgi, N., Napoli, F., Allegri, A. E. M., Olivieri, I., Bertelli, E., Gallizia, A., ... & Maghnie, M. (2012). Diabetes insipidus–diagnosis and management. Hormone research in paediatrics, 77(2), 69-84.
3. Norris, M. M. (2009). Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study. Diabetologia, 2064-2071.
4. Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2014). Type 1 diabetes. The lancet, 383(9911), 69-82.
5. Kumar, R., Saha, P., Kumar, Y., Sahana, S., Dubey, A., & Prakash, O. (2020). A review on diabetes mellitus: type1 & Type2. World Journal of Pharmacy and Pharmaceutical Sciences, 9(10), 838-850.
6. Paschou, S. A., Papadopoulou-Marketou, N., Chrousos, G. P., & Kanaka-Gantenbein, C. (2018). On type 1 diabetes mellitus pathogenesis. Endocrine connections, 7(1), R38-R46.
7. Powers, A. C. (2021). Type 1 diabetes mellitus: much progress, many opportunities. The Journal of clinical investigation, 131(8).
8. Pociot, F., & McDermott, M. F. (2002). Genetics of type 1 diabetes mellitus. Genes & Immunity, 3(5), 235-249.
9. Morran, M. P., Vonberg, A., Khadra, A., & Pietropaolo, M. (2015). Immunogenetics of type 1 diabetes mellitus. Molecular aspects of medicine, 42, 42-60.
10. Ilonen, J., Lempainen, J., & Veijola, R. (2019). The heterogeneous pathogenesis of type 1 diabetes mellitus. Nature Reviews Endocrinology, 15(11), 635-650.
11. Daneman, D. (2006). Type 1 diabetes. The Lancet, 367(9513), 847-858.
12. DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., ... & Weiss, R. (2015). Type 2 diabetes mellitus. Nature reviews Disease primers, 1(1), 1-22.
13. Chatterjee, S., Khunti, K., & Davies, M. J. (2017). Type 2 diabetes. The lancet, 389(10085), 2239-2251.
14. Vijan, S. (2010). Type 2 diabetes. Annals of internal medicine, 152(5), ITC3-1.
15. Lebovitz, H. E. (1999). Type 2 diabetes: an overview. Clinical chemistry, 45(8), 1339-1345.
16. Taylor, S. I. (1999). Deconstructing type 2 diabetes. Cell, 97(1), 9-12.
17. Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., ... & Martín, C. (2020). Pathophysiology of type 2 diabetes mellitus. International journal of molecular sciences, 21(17), 6275.
18. Chen, L., Magliano, D. J., & Zimmet, P. Z. (2012). The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nature reviews endocrinology, 8(4), 228-236.
19. Tuomi, T. (2005). Type 1 and type 2 diabetes: what do they have in common? Diabetes, 54(suppl_2), S40-S45.
20. Scheen, A. J. (2003). Pathophysiology of type 2 diabetes. Acta Clinica Belgica, 58(6), 335341.
21. Nolan, C. J., Damm, P., & Prentki, M. (2011). Type 2 diabetes across generations: from pathophysiology to prevention and management. The Lancet, 378(9786), 169-181.
22. Deshpande, A. D., Harris-Hayes, M., & Schootman, M. (2008). Epidemiology of diabetes and diabetes-related complications. Physical therapy, 88(11), 1254-1264.
23. Papatheodorou, K., Banach, M., Bekiari, E., Rizzo, M., & Edmonds, M. (2018). Complications of diabetes 2017. Journal of diabetes research, 2018.
24. Scott A., Chambers D., Goyder E., O’Cathain A. Socioeconomic inequalities in mortality, morbidity, and diabetes management for adults with type 1 diabetes: a systematic review. PLoS One. 2017;12.
25. Shuldiner A. R., Yang R., Gong D.-W. Resistin, obesity, and insulin resistance — the emerging role of the adipocyte as an endocrine organ. The New England Journal of Medicine. 2001;345(18):1345–1346.
26. Banday, M. Z., Sameer, A. S., & Nissar, S. (2020). Pathophysiology of diabetes: An overview. Avicenna journal of medicine, 10(04), 174-188. https://en.wikipedia.org/wiki/Diabetes
27. Duby JJ, Campbell RK, Setter SM, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 2004; 61: 160-73
28. Ng DP, Krolewski AS. Molecular genetic approaches for studying the etiology of diabetic nephropathy. Curr Mol Med 2005; 5: 509- 25.
29. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nature Clin Prac Endocrinol Metab 2008; 4: 444-52.
30. Madsen-Bouterse SA, Kowluru RA. Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endo Metab Disor 2008; 9: 315-27.
31. Pendsey S. Understanding diabetic foot. Int J Diabetes Dev Ctries 2010; 30: 75-9.
32. Oumeish OY. Skin disorders in patients with diabetes. Clin Dermatol 2008; 26: 235-42.
33. Lotfy, M., Adeghate, J., Kalasz, H., Singh, J., & Adeghate, E. (2017). Chronic complications of diabetes mellitus: a mini review. Current diabetes reviews, 13(1), 3-10.
34. https://en.wikipedia.org/wiki/Jasmine
35. Mourya, N. M. N., Bhopte, D. B. D., & Sagar, R. S. R. (2017). A review on Jasminum Sambac: A potential medicinal plant. International Journal of Indigenous Herbs and Drugs, 13-16.
36. Joy, P., & Raja, D. P. (2008). Anti-bacterial activity studies of Jasminum grandiflorum and Jasminum sambac. Ethnobotanical leaflets, 2008(1), 59.
37. Ahmed, N., Hanani, Y. A., Ansari, S. Y., & Anwar, S. (2016). Jasmine (Jasminum Sambac L., Oleaceae) oils. In Essential oils in food preservation, flavor, and safety (pp. 487-494). Academic Press.
38. Silalahi, M. (2023). Jasmine (Jasminum sambac (L.) Aiton): potential utilization and bioactivity. Asian Journal of Research in Agriculture and Forestry, 9(2), 28-36. https://en.wikipedia.org/wiki/Stevia_rebaudiana
39. https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/stevia
40. Yadav, A. K., Singh, S., Dhyani, D., & Ahuja, P. S. (2011). A review on the improvement of stevia [Stevia rebaudiana (Bertoni)]. Canadian journal of plant science, 91(1), 1-27.
41. Goyal, S. K., Samsher, N., & Goyal, R. (2010). Stevia (Stevia rebaudiana) a bio-sweetener: a review. International journal of food sciences and nutrition, 61(1), 1-10.
42. Ghaheri, M., Kahrizi, D., & Bahrami, G. (2017). Effect of mannitol on some morphological characteristics of in vitro stevia rebaudiana Bertoni. Biharean Biologist, 11(2), 94-97.
43. Mlambo, R., Wang, J., & Chen, C. (2022). Stevia rebaudiana, a versatile food ingredient: The chemical composition and medicinal properties. Journal of Nanomaterials, 2022(1), 3573005.
44. Jan, S. A., Habib, N., Shinwari, Z. K., Ali, M., & Ali, N. (2021). The anti-diabetic activities of natural sweetener plant Stevia: an updated review. SN Applied Sciences, 3, 1-6.
45. Pérez, E., González, C., Vaillant, F., & Lares, M. (2016). Stevia derivative and its potential uses in diabetic-directed foods. Review. Journal of Nutrients, 3(1), 1-20.
46. Chowdhury, A. I., Rahanur Alam, M., Raihan, M. M., Rahman, T., Islam, S., & Halima, O. (2022). Effect of stevia leaves (Stevia rebaudiana Bertoni) on diabetes: A systematic review and meta‐analysis of preclinical studies. Food Science & Nutrition, 10(9), 2868-2878.
47. Masoumi, S. J., Ranjbar, S., & Keshavarz, V. (2020). The effectiveness of stevia in diabetes mellitus: A review. International journal of nutrition sciences, 5(2), 45-49.
48. Shivanna, N., Naika, M., Khanum, F., & Kaul, V. K. (2013). Antioxidant, anti-diabetic and renal protective properties of Stevia rebaudiana. Journal of Diabetes and its Complications, 27(2), 103-113.
Article Sidebar
Published
Dec 11, 2024
Article Details
How to Cite
Nensi Parakhiya, Vaidehi Gurjar, & Dr. Pragnesh Patani. (2024). THERAPEUTIC POTENTIAL OF JASMINUM SAMBAC IN DIABETES: A REVIEW. Journal of Population Therapeutics and Clinical Pharmacology, 31(11), 1113-1124. https://doi.org/10.53555/611n7h22
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Nensi Parakhiya
Student, Khyati College of Pharmacy, Palodia, Ahmedabad.
Vaidehi Gurjar
Assistant Professor, Khyati College of Pharmacy, Palodia, Ahmedabad.
Dr. Pragnesh Patani
Principal, Khyati College of Pharmacy, Palodia, Ahmedabad.
How to Cite
Nensi Parakhiya, Vaidehi Gurjar, & Dr. Pragnesh Patani. (2024). THERAPEUTIC POTENTIAL OF JASMINUM SAMBAC IN DIABETES: A REVIEW. Journal of Population Therapeutics and Clinical Pharmacology, 31(11), 1113-1124. https://doi.org/10.53555/611n7h22